Envision Pharma Group (Envision) today announces the appointment of Adam B. Deutsch as General Counsel and member of its Executive Leadership Team. In this position he will lead the company’s global legal strategy through advisement on a broad range of legal, ethical, and governance matters.

Adam was most recently the Chief Business Officer & General Counsel for Clario that holds leading market positions in electronic clinical outcome assessment (eCOA), medical imaging, cardiac safety, and respiratory solutions. Prior to that, he held several executive leadership roles, including Chief Transformation Officer and General Counsel for ConvaTec, a FTSE 100 global medtech company.

Adam was instrumental in identifying transformational business opportunities while navigating enterprise risk with two major private equity healthcare exits, through ConvaTec’s $1.8 billion IPO and Biomet’s $13.35 billion merger with Zimmer Holdings.

“I am so excited to welcome Adam to the Envision team,” shares Howard Miller, CEO of Envision Pharma Group. “Adam’s depth of knowledge and proven leadership capabilities will guide Envision’s legal strategy and operations, while his management of our talented legal team will be crucial to the success of our organization.”

Adam adds, “I’m excited to join Envision and serve our employees and clients. Envision offers uniquely compelling solutions with market-leading and next-generation technology, a world-class team of over 1400 experts, and highly in-demand services that enable our clients to better serve patients and thrive in a complex and rapidly changing healthcare environment. This dynamic team alongside a comprehensive solutions-oriented service platform, position the company for its next phase of growth and it’s a privilege for me to be able to help achieve these aspirations.”